DE3673273T2 - Prophylaktische und therapeutische mittel fuer kreislaufkrankheiten. - Google Patents

Prophylaktische und therapeutische mittel fuer kreislaufkrankheiten.

Info

Publication number
DE3673273T2
DE3673273T2 DE8686106817T DE3673273T DE3673273T2 DE 3673273 T2 DE3673273 T2 DE 3673273T2 DE 8686106817 T DE8686106817 T DE 8686106817T DE 3673273 T DE3673273 T DE 3673273T DE 3673273 T2 DE3673273 T2 DE 3673273T2
Authority
DE
Germany
Prior art keywords
prophylactic
therapeutic agents
diseases
circular
circular diseases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE8686106817T
Other languages
English (en)
Other versions
DE3673273D1 (de
Inventor
Hiroyoshi Nishi
Toshiaki Watanabe
Satoshi Yuki
Yasuhiro Morinaka
Katsuhiko Iseki
Hiroko Sakurai
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mitsubishi Kasei Corp
Original Assignee
Mitsubishi Kasei Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from JP10579885A external-priority patent/JPS61263917A/ja
Priority claimed from JP24805785A external-priority patent/JPS62108814A/ja
Application filed by Mitsubishi Kasei Corp filed Critical Mitsubishi Kasei Corp
Publication of DE3673273D1 publication Critical patent/DE3673273D1/de
Application granted granted Critical
Publication of DE3673273T2 publication Critical patent/DE3673273T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C07D231/20—One oxygen atom attached in position 3 or 5
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C07D231/20—One oxygen atom attached in position 3 or 5
    • C07D231/22—One oxygen atom attached in position 3 or 5 with aryl radicals attached to ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C07D231/20—One oxygen atom attached in position 3 or 5
    • C07D231/22—One oxygen atom attached in position 3 or 5 with aryl radicals attached to ring nitrogen atoms
    • C07D231/26—1-Phenyl-3-methyl-5- pyrazolones, unsubstituted or substituted on the phenyl ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/28—Two oxygen or sulfur atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE8686106817T 1985-05-20 1986-05-20 Prophylaktische und therapeutische mittel fuer kreislaufkrankheiten. Expired - Fee Related DE3673273T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP10579885A JPS61263917A (ja) 1985-05-20 1985-05-20 脳機能正常化剤
JP24805785A JPS62108814A (ja) 1985-11-07 1985-11-07 過酸化脂質生成抑制剤

Publications (2)

Publication Number Publication Date
DE3673273D1 DE3673273D1 (de) 1993-04-29
DE3673273T2 true DE3673273T2 (de) 1993-09-09

Family

ID=26446032

Family Applications (1)

Application Number Title Priority Date Filing Date
DE8686106817T Expired - Fee Related DE3673273T2 (de) 1985-05-20 1986-05-20 Prophylaktische und therapeutische mittel fuer kreislaufkrankheiten.

Country Status (4)

Country Link
US (1) US4857542A (de)
EP (1) EP0208874B1 (de)
DE (1) DE3673273T2 (de)
DK (1) DK169672B1 (de)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3788737T2 (de) * 1986-01-29 1994-05-05 Sumitomo Chemical Co Indazol-Verbindungen, Verfahren zu deren Herstellung, deren Anwendung und Zwischenprodukte.
EP0269030B1 (de) * 1986-11-20 1994-05-04 Mitsubishi Kasei Corporation Die Bildung von Lipid-peroxiden hemmende Zusammenstzung und dafür geeignete Verbindungen
IL84944A (en) * 1987-01-19 1992-02-16 Ici Plc Pharmaceutical compositions containing 1,2-dihydro-3h-indazolone derivatives,some new such compounds and their preparation
US5233044A (en) * 1989-06-08 1993-08-03 Millipore Corporation Active esters for solid phase peptide synthesis
US5264451A (en) * 1992-04-07 1993-11-23 American Home Products Corporation Process for treating hyperglycemia using trifluoromethyl substituted 3H-pyrazol-3-ones
JPH0725765A (ja) * 1993-07-07 1995-01-27 Mitsubishi Chem Corp 眼疾患用薬剤
JP3065506B2 (ja) * 1995-04-03 2000-07-17 株式会社資生堂 ピラゾリジン誘導体及びラジカルスカベンジャー、脳梗塞抑制剤、脳浮腫抑制剤
DE19518082A1 (de) * 1995-05-17 1996-11-21 Merck Patent Gmbh 4(-Arylaminomethylen)-2,4-dihydropyrazol-3-one
DE19756115A1 (de) * 1997-12-17 1999-06-24 Basf Ag Substituierte Phenylpyrazolone, Verfahren und Zwischenprodukte zu ihrer Herstellung und ihre Verwendung zur Bekämpfung von Schadpilzen und tierischen Schädlingen
DE60138385D1 (de) * 2000-06-29 2009-05-28 Mei Co Ltd Heilmittel zur behandlung von erkrankungen des sehnervs
US6933310B1 (en) 2000-10-24 2005-08-23 Mitsubishi Pharma Corporation Therapeutic agent for amyotrophic lateral sclerosis (ALS)
CA2446837C (en) 2001-05-11 2012-01-03 Mitsubishi Pharma Corporation Stable high-concentration injection containing pyrazolone derivative
CN100398104C (zh) * 2001-09-14 2008-07-02 三菱制药株式会社 抗血栓药和吡唑啉酮衍生物的组合药物
WO2003064395A1 (fr) * 2002-01-31 2003-08-07 President Of National Center Of Neurology And Psychiatry Agents preventifs et therapeutiques destines a lutter contre des maladies neurodegeneratives
WO2003066051A1 (fr) * 2002-02-06 2003-08-14 Mitsubishi Pharma Corporation Agent preventif et/ou therapeutique utilise dans le traitement et/ou la prevention des troubles cardiaques
JP2005343789A (ja) * 2002-03-15 2005-12-15 Mitsubishi Pharma Corp 低酸素性虚血性脳障害予防・治療剤
JPWO2003105909A1 (ja) * 2002-06-13 2005-10-13 三菱ウェルファーマ株式会社 肝虚血再灌流傷害の予防及び／又は治療のための医薬並びに移植肝臓の保護剤
JPWO2004013107A1 (ja) * 2002-08-05 2006-09-21 三菱ウェルファーマ株式会社 脊髄損傷による障害の予防及び／又は治療のための医薬
US7312239B2 (en) * 2002-09-04 2007-12-25 Mitsubishi Pharma Corporation Medicament for prevention and/or therapy of arterial wall disorder
WO2004022543A1 (ja) * 2002-09-09 2004-03-18 Mitsubishi Pharma Corporation 炎症性腸疾患の予防及び／又は治療のための医薬
WO2004029042A1 (en) * 2002-09-26 2004-04-08 Pfizer Limited Pyrazole derivatives as reverse transcriptase inhibitors
US7230025B2 (en) 2002-09-26 2007-06-12 Pfizer, Inc. Pyrazole derivatives
AU2003282679A1 (en) * 2002-10-04 2004-05-04 Arena Pharmaceuticals, Inc. Hydroxypyrazoles for use against metabolic-related disorders
JP2006096664A (ja) * 2002-10-18 2006-04-13 Mitsubishi Pharma Corp 肝繊維化抑制剤
WO2004037249A1 (ja) * 2002-10-28 2004-05-06 Mitsubishi Pharma Corporation 心肺蘇生後の機能障害の改善剤
JPWO2004063167A1 (ja) * 2003-01-10 2006-05-18 三菱ウェルファーマ株式会社 血液脳関門破綻抑制剤
WO2005046680A1 (ja) * 2003-11-12 2005-05-26 Lead Chemical Co., Ltd. 経皮吸収型脳保護剤
EP1714960B1 (de) 2004-02-09 2018-03-28 Mitsubishi Tanabe Pharma Corporation Neues therapeutisches mittel gegen amyotrophische lateralsklerose (als) oder einer als zuschreibbaren krankheit
JP5198852B2 (ja) 2004-08-10 2013-05-15 田辺三菱製薬株式会社 脳梗塞に関連する脳血管障害の治療に有用なピラゾロン化合物
US7850723B1 (en) * 2005-11-28 2010-12-14 Innercool Therapies, Inc. Method and apparatus for patient temperature control employing titration of therapy using EEG signals
CN101367763B (zh) * 2007-08-17 2012-06-27 深圳泛胜塑胶助剂有限公司 1-苯基-3-甲基-5-吡唑酮的合成工艺
TWI430789B (zh) 2007-11-22 2014-03-21 Mitsubishi Plastics Inc Plastic containers containing cyclic polyolefin layers
CN101524352A (zh) 2008-03-04 2009-09-09 江苏先声药物研究有限公司 一种含有3-甲基-1-苯基-2-吡唑啉-5-酮的组合物
CN101830852B (zh) * 2010-03-22 2012-05-09 海南美兰史克制药有限公司 一种新路线的依达拉奉化合物
CN102241631A (zh) * 2010-05-13 2011-11-16 吉林省博大制药有限责任公司 依达拉奉原料的制备方法
CN102180834B (zh) * 2011-03-24 2012-09-26 江苏正大丰海制药有限公司 一种依达拉奉的制备方法
TR201905098T4 (tr) 2011-09-05 2019-05-21 Mitsubishi Tanabe Pharma Corp Amyotrofik lateral sklerozun tedavi edilmesi ya da amyotrofik lateral skleroz fazının ilerleyişinin önlenmesi için farmasötik ajan
CN103588709B (zh) * 2012-08-17 2015-09-09 上海医药工业研究院 一种依达拉奉的制备方法
WO2014074218A1 (en) 2012-11-12 2014-05-15 Redwood Bioscience, Inc. Compounds and methods for producing a conjugate
JP2017222575A (ja) 2014-09-19 2017-12-21 田辺三菱製薬株式会社 眼科疾患予防治療剤
CN104326984A (zh) * 2014-10-10 2015-02-04 河南明德科润医药科技有限责任公司 一种高纯度药用注射级依达拉奉原料的合成方法
CN106117144B (zh) * 2016-06-24 2019-01-29 合肥久诺医药科技有限公司 一种高纯度依达拉奉的合成工艺
WO2019070932A1 (en) 2017-10-04 2019-04-11 Mitsubishi Tanabe Pharma Corporation METHOD OF TREATING AMYOTROPHIC LATERAL SCLEROSIS AND METHOD OF PREVENTING THE PROGRESSION OF AMYOTROPHIC LATERAL SCLEROSIS
CA3078320A1 (en) 2017-10-04 2019-04-11 Mitsubishi Tanabe Pharma Corporation Method for treating amyotrophic lateral sclerosis and method for suppressing progress of amyotrophic lateral sclerosis
WO2019167178A1 (ja) 2018-02-28 2019-09-06 田辺三菱製薬株式会社 ３－メチル－１－フェニル－２－ピラゾリン－５－オン原薬の分析方法、筋萎縮性側索硬化症の治療および筋萎縮性側索硬化症の進行抑制、ならびに、３－メチル－１－フェニル－２－ピラゾリン－５－オン原薬を含む薬剤の製造方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1723545A (en) * 1925-10-21 1929-08-06 Ig Farbenindustrie Ag Process of preparing 1-phenyl-3-methyl-5-pyrazolone
DE1003215B (de) * 1954-08-07 1957-02-28 Hoechst Ag Verfahren zur Herstellung von 1-Benzyl-3-methyl-pyrazolon-(5)
US3514465A (en) * 1966-12-30 1970-05-26 Degussa Certain thiazolyl- and pyridinylaminoketones
US3479369A (en) * 1967-04-05 1969-11-18 Uniroyal Inc Alkyl- or aryl-4-antipyrylmonosulfides and method for preparing same
IT1044784B (it) * 1970-12-15 1980-04-21 Italfarmaco Spa Farmaco adnattivita analgesica e antiinfiammatoria
US4112227A (en) * 1973-04-17 1978-09-05 Bayer Aktiengesellschaft Pyrazol-5-ones
US4000294A (en) * 1973-04-17 1976-12-28 Bayer Aktiengesellschaft Pyrazol-5-ones
US4005215A (en) * 1973-04-17 1977-01-25 Bayer Aktiengesellschaft Pyrazol-5-ones
DE2319278C2 (de) * 1973-04-17 1986-02-20 Bayer Ag, 5090 Leverkusen Pharmazeutisches Mittel
DE2427272C3 (de) * 1974-06-06 1981-10-01 Bayer Ag, 5090 Leverkusen 1-(2-(β-Naphthyloxy)-äthyl)-3-methyl -pyrazolon-(5), Verfahren sowie Verwendung als Antithrombotikum
DE2461039A1 (de) * 1974-12-23 1976-06-24 Thiemann Chem Pharm Fab Arzneimittel
JPS5813556B2 (ja) * 1975-12-22 1983-03-14 タイホウヤクヒンコウギヨウ カブシキガイシヤ ピラノピラゾ−ル −３− カルボンサンユウドウタイノセイホウ
JPS5770871A (en) * 1980-10-17 1982-05-01 Konishiroku Photo Ind Co Ltd Synthetic method of magneta coupler
DK143684A (da) * 1983-03-12 1984-09-13 Bayer Ag Anvendelse af pyrazolonderivater som lipoxygenasehaemmer ved terapi af isaer ischaemi og hjerterytmeforstyrrelser
DE3312581A1 (de) * 1983-04-08 1984-10-11 Bayer Ag, 5090 Leverkusen Verwendung von pyrazolonderivaten bei der bekaempfung des wachstums von tumorzellen und der metastasenbildung, arzneimittel hierfuer und verfahren zu deren herstellung
US4550119A (en) * 1983-05-23 1985-10-29 Warner-Lambert Company 2,4-Dihydro-5-[(substituted)phenyl]-4,4-disubstituted-3H-pyrazol-3-ones
DE3443308A1 (de) * 1984-11-28 1986-05-28 Bayer Ag, 5090 Leverkusen 1-heteroaryl-4-aryl-pyrazolin-5-one zur verwendung als arzneimittel

Also Published As

Publication number Publication date
DE3673273D1 (de) 1993-04-29
US4857542A (en) 1989-08-15
DK227186D0 (da) 1986-05-16
EP0208874B1 (de) 1993-03-24
EP0208874A1 (de) 1987-01-21
DK169672B1 (da) 1995-01-09
DK227186A (da) 1986-11-21

Similar Documents

Publication Publication Date Title
DE3673273D1 (de) Prophylaktische und therapeutische mittel fuer kreislaufkrankheiten.
DE3680943D1 (de) Therapeutische mittel zur oralen verabreichung.
DK441586D0 (da) Kirurgisk indretning
DE3889245D1 (de) Integrierter und kontrollierter Leistungs-MOSFET.
DE3688895D1 (de) Kosmetisches mittel.
DE3684108D1 (de) Zementformende mittel.
AT385664B (de) Elektromedizinisches therapiegeraet
DE3674440D1 (de) Therapeutische partikel.
DE3786714D1 (de) Therapeutisches mittel fuer hautgeschwuere.
DE3679764D1 (de) Zaepfchen und grundlage dafuer.
DE220574T1 (de) Menschliches interferon-beta2a und interferon-beta2b
AU590640B2 (en) Dementia-improving and therapeutic agents
DE3671010D1 (de) Antiallergische mittel.
DE3687097D1 (de) Therapeutisches mittel zur behandlung haematopoietischer krankheiten.
DK456686A (da) Stabiliseret human prourokinase
DE3650451T2 (de) Geisteskrankheittherapeutisches Mittel
DE3674017D1 (de) Oxalursaeure-derivate und pharmazeutisches mittel.
DE3688625T2 (de) Therapeutische Bandage.
DE3855561D1 (de) Mittel zur verhütung von zahnbelag und belagabhängigen krankheiten
DK316386D0 (da) Terapeutisk aktive benzamider og fremgangsmaade til fremstilling af saadanne
IT8720352A0 (it) Sostanza profilattica e terapeutica per disturbi epatici.
DE3577985D1 (de) Organotitan-verbindungen und oberflaechenbehandlungsmittel.
KR870006433U (ko) 미용 맛사지기
ATE55058T1 (de) Wurmtoetende chinolinylacylhydrazone und mittel.
IT8519407A0 (it) Preparazioni farmaceutiche, igieniche e presidi medico-chirurgici eloro impiego

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee